IDH1 and intrahepatic cholangiocarcinoma: Their potential role as prognostic and predictive markers has been investigated: IDH1/2 mutations do not implicate alternative treatment or additional prognostically impactful information in most of the above diseases, whereas IDH1/2 mutations may lead to treatment with biologic actives in IDH1/2-mutated intrahepatic cholangiocarcinoma or differential diagnosis in neuropathology [14, 18, 25, 27, 31, 37, 42, 43, 46, 47, 49].